Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial.
Stewart AK, Vescio R, Schiller G, Ballester O, Noga S, Rugo H, Freytes C, Stadtmauer E, Tarantolo S, Sahebi F, Stiff P, Meharchard J, Schlossman R, Brown R, Tully H, Benyunes M, Jacobs C, Berenson R, White M, DiPersio J, Anderson KC, Berenson J.
Stewart AK, et al. Among authors: vescio r.
J Clin Oncol. 2001 Sep 1;19(17):3771-9. doi: 10.1200/JCO.2001.19.17.3771.
J Clin Oncol. 2001.
PMID: 11533101
Clinical Trial.